- The organizers of this 256th European NeuroMuscular Center (ENMC) workshop welcomed 20 participants from 10 countries (Belgium, China, Czech Republic, France, Germany, Netherlands, Spain, Sweden, United Kingdom and United States of America), comprising clinicians from different disciplines, laboratory specialists, researchers and patient representatives. Due to COVID-19 restrictions about half of the participants attended the meeting on-line, while the other half gathered in Amsterdam on 8-10 October 2021 for this workshop on the harmonization of myositis specific autoantibodies (MSA) and myositis associated autoantibodies (MAA).
- Organizers of this 239th ENMC workshop welcomed 22 participants from 12 countries worldwide (Belgium, Canada, China, the Czech Republic, France, Germany, Japan, The Netherlands, Spain, Sweden, the United Kingdom, and the United States of America) to Amsterdam on 14–16 December 2018 for this workshop on the clinicopathological classification of dermatomyositis (DM).
- Organizers of this 224th ENMC workshop welcomed 19 participants from 8 countries worldwide (Belgium, France, Germany, Japan, The Netherlands, Sweden, the United Kingdom, and the United States of America) to Zandvoort on 14–16 October 2016 for this workshop for clinicopathological classification of immune-mediated necrotizing myopathies.
- The 213th ENMC International Workshop, “Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies (IIM),” took place in Heemskerk, The Netherlands, on September 18–20, 2015, and was attended by 18 experts in IIM from 7 specialties (dermatology, internal medicine, neurology, pediatrics, physiotherapy, pulmonology, and rheumatology) and 3 patient representatives from 8 countries (Belgium, France, Norway, The Netherlands, Spain, Sweden, the United Kingdom, and the United States of America).
- The idiopathic inflammatory myopathies (IM) are a heterogeneous group of diseases and diagnosis often necessitates a muscle biopsy. Five main entities are recognized: (1) dermatomyositis (DM); (2) polymyositis (PM); (3) necrotizing autoimmune myopathy (NAM); (4) sporadic inclusion body myositis (IBM); and (5) non-specific myositis. Other entities include granulomatous myopathy, macrophagic myofasciitis, and eosinophilic fasciitis (Shulman's syndrome). The pathological classification and subsequent identification of disease subgroups are extremely important for assessing treatment options and prognosis in the individual patient, yet classification criteria have not been standardized and validated.
- This 1-day workshop was organized by Olivier Benveniste and David Hilton-Jones and assembled 20 clinicians, pathologists and researchers (see the list of participants) from four countries (UK, USA, Austria, France). This workshop followed one held in London 1 year earlier with some common participants  in order to reinforce a collaborative interface between several international groups actively investigating the clinical features, pathogenesis and treatment of sporadic inclusion body myositis (sIBM).